Home > Healthcare > Medical Devices > Diagnostic Devices > point of care coagulation testing products market
Get a free sample of Point of Care Coagulation Testing Products Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Point of Care Coagulation Testing Products Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Governments globally prioritize early detection of blood-related diseases to reduce healthcare burdens, leading to a surge in initiatives including research funding, awareness campaigns, and subsidies for vital medical devices such as point of care coagulation testing products. For instance, in March 2022, the National Hemophilia Foundation launched the "Starts the Conversation" initiative for bleeding disorders awareness month. This initiative was designed to spotlight a diverse spectrum of experiences, encompassing disease conditions, research pursuits, educational endeavours, and advocacy efforts.
Furthermore, technological progress has yielded the creation of increasingly precise, dependable, and user-friendly point of care coagulation testing products. These advancements encompass refined sensors, automation, integration with electronic health records (EHRs), and seamless connectivity to smartphones or tablets. The heightened accuracy and simplified usage of these devices enhance healthcare providers' trust in their application.
Abbott Laboratories, Helena Laboratories, Thermo Fisher Scientific Inc, Alere Inc., Medtronic plc, Sysmex Corporation, Diagnostica Stago Sas, and Nihon Kohden Corporation are some of the major point of care coagulation testing product companies worldwide.
U.S. industry registered 788 million in revenue in 2022 and is expected to witness significant CAGR from 2023-2032 owing to the presence of robust healthcare infrastructure and the rising integration of advanced medical technologies in the region.
The prothrombin time testing segment recorded USD 1.2 billion in 2022 on account of higher application in anticoagulant therapy monitoring, bleeding risk assessment, and blood disorder management.
Point of care coagulation testing products market size was USD 2.3 billion in 2022 and will reach USD 4.8 billion by 2032 due to the rising number of chronic blood disorders worldwide.